-
1.发明授权COMPOSITIONS FOR USE IN CELL AND GENE BASED METHODS TO IMPROVE CARDIAC FUNCTION 有权用于改善基于细胞和基因的方法以改善心脏功能的组合物
公开(公告)号：EP2714709B1
公开(公告)日：2018-04-18
申请号：EP12790042.1
申请日：2012-05-29
发明人： REGNIER, Michael , LAFLAMME, Michael , MURRY, Charles , KORTE, F., Steven , LUNDY, Scott , HAUSCHKA, Stephen, Denison , CHAMBERLAIN, Jeffrey, S. , ODOM, Guy
CPC分类号： C12N5/0657 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0375 , A61K9/0019 , A61K35/34 , A61K48/005 , C07K14/4716 , C12N7/00 , C12N9/0093 , C12N15/8509 , C12N15/86 , C12N2750/14132 , C12N2750/14143 , C12N2799/022 , C12N2799/025 , C12Y117/04001 , C12Y117/04002
摘要： Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.
-
公开(公告)号：EP2833930B1
公开(公告)日：2018-05-30
申请号：EP13771865.6
申请日：2013-03-15
申请人： University of Washington through its Center for Commercialization , Kim, Deok-Ho , Laflamme, Michael , Murry, Charles , Gupta, Kshitiz , Yoo, Hyok , Jiao, Alex
发明人： KIM, Deok-Ho , LAFLAMME, Michael , MURRY, Charles , GUPTA, Kshitiz , YOO, Hyok , JIAO, Alex
CPC分类号： C12N5/0606 , A61K48/00 , A61L27/14 , A61L27/18 , A61L27/3826 , A61L27/3834 , A61L27/3873 , A61L27/50 , A61L2400/12 , A61L2400/18 , B01L3/5085 , B01L2300/0851 , B01L2300/0896 , B01L2400/086 , C12M21/08 , C12M25/14 , C12N5/0657 , C12N5/0658 , C12N5/0696 , C12N2503/02 , C12N2533/30 , C12N2533/40 , C12N2535/00 , C08L67/04
摘要： The present invention generally relates to the field of cell growth and tissue engineering, in particular, tissue engineered compositions comprising a nanotextured substrate which is structurally configured for growth of cells in an anatomically correct adult phenotype in vitro. In particular, described herein are nanotextured substrates which are structurally configured for the anisotropic organization, maturation, and growth of in vitro-differentiated muscle cells, such as cardiomyocytes, and methods for the production and use thereof in varying sizes, nanotextures and substrate rigidities. In vitro-differentiated cardiomyocytes grown on the nanotextured substrates described herein are better-differentiated and more closely mimic adult cardiac tissue than the same cells grown on a non-textured substrate of the same composition. The nanotextured substrate/cell constructs provide a platform for screening to predict the effect of test agents or drugs on, for example, human cardiac tissue, including patient-derived tissue, or for the identification of agents that effect various cardiac functional parameters.
-
公开(公告)号：EP2833930A1
公开(公告)日：2015-02-11
申请号：EP13771865.6
申请日：2013-03-15
申请人： University Of Washington Through Its Center For Commercialization , Kim, Deok-Ho , Laflamme, Michael , Murry, Charles , Gupta, Kshitiz , Yoo, Hyok , Jiao, Alex
发明人： KIM, Deok-Ho , LAFLAMME, Michael , MURRY, Charles , GUPTA, Kshitiz , YOO, Hyok , JIAO, Alex
CPC分类号： C12N5/0606 , A61K48/00 , A61L27/14 , A61L27/18 , A61L27/3826 , A61L27/3834 , A61L27/3873 , A61L27/50 , A61L2400/12 , A61L2400/18 , B01L3/5085 , B01L2300/0851 , B01L2300/0896 , B01L2400/086 , C12M21/08 , C12M25/14 , C12N5/0657 , C12N5/0658 , C12N5/0696 , C12N2503/02 , C12N2533/30 , C12N2533/40 , C12N2535/00 , C08L67/04
摘要： The present invention generally relates to the field of cell growth and tissue engineering, in particular, tissue engineered compositions comprising a nanotextured substrate which is structurally configured for growth of cells in an anatomically correct adult phenotype in vitro. In particular, described herein are nanotextured substrates which are structurally configured for the anisotropic organization, maturation, and growth of in vitro-differentiated muscle cells, such as cardiomyocytes, and methods for the production and use thereof in varying sizes, nanotextures and substrate rigidities. In vitro-differentiated cardiomyocytes grown on the nanotextured substrates described herein are better-differentiated and more closely mimic adult cardiac tissue than the same cells grown on a non-textured substrate of the same composition. The nanotextured substrate/cell constructs provide a platform for screening to predict the effect of test agents or drugs on, for example, human cardiac tissue, including patient-derived tissue, or for the identification of agents that effect various cardiac functional parameters.
-
公开(公告)号：EP2714709A2
公开(公告)日：2014-04-09
申请号：EP12790042.1
申请日：2012-05-29
发明人： REGNIER, Michael , LAFLAMME, Michael , MURRY, Charles , KORTE, F., Steven , LUNDY, Scott , HAUSCHKA, Stephen, Denison , CHAMBERLAIN, Jeffrey, S.
CPC分类号： C12N5/0657 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0375 , A61K9/0019 , A61K35/34 , A61K48/005 , C07K14/4716 , C12N7/00 , C12N9/0093 , C12N15/8509 , C12N15/86 , C12N2750/14132 , C12N2750/14143 , C12N2799/022 , C12N2799/025 , C12Y117/04001 , C12Y117/04002
摘要： Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.
-
-
-
搜索结果
4 条记录 (耗时 0.02 秒)
